FDA Taps Murphy to Head Generic Drugs Office

FDA has selected CDER Office of Generic Drugs (OGD) safety and clinical evaluation acting director Iilun Murphy to serve as the next OGD director, replacing Sally Choe, who left the agency eight months ago to pursue opportunities outside the agency. CDER Office of Lifecycle Drug Products director Susan Rosencrance, who has served as acting OGD director since October, will assist with the transition period as the acting principal deputy director for OGD before returning to her previous role at the end of August, according to an agency email announcing the change.

Murphy began her FDA career in 2007 as a medical officer in the Division of Gastroenterology Products in the Office of New Drugs. She is a board-certified pediatrician and an assistant clinical professor of pediatrics at the George Washington University School of Medicine. Murphy has a bachelor’s degree from Cornell University and a medical degree from Stanford University.